These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20498618)

  • 1. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
    Sowers JR; Raij L; Jialal I; Egan BM; Ofili EO; Samuel R; Zappe DH; Purkayastha D; Deedwania PC
    J Hypertens; 2010 Aug; 28(8):1761-9. PubMed ID: 20498618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
    Ofili EO; Zappe DH; Purkayastha D; Samuel R; Sowers JR
    Am J Ther; 2013 Jan; 20(1):2-12. PubMed ID: 22248871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
    Weir MR; Ferdinand KC; Flack JM; Jamerson KA; Daley W; Zelenkofske S
    Hypertension; 2005 Sep; 46(3):508-13. PubMed ID: 16116046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
    Zappe D; Papst CC; Ferber P;
    Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
    Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
    Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
    Destro M; Crikelair N; Yen J; Glazer R
    Vasc Health Risk Manag; 2010 Sep; 6():821-7. PubMed ID: 20859551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
    Malacco E; Varì N; Capuano V; Spagnuolo V; Borgnino C; Palatini P;
    Clin Ther; 2003 Nov; 25(11):2765-80. PubMed ID: 14693303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
    Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
    J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker.
    Uzu T; Sakaguchi M; Yokomaku Y; Kume S; Kanasaki M; Isshiki K; Araki SI; Sugiomoto T; Koya D; Haneda M; Kashiwagi A
    Clin Exp Nephrol; 2009 Aug; 13(4):300-306. PubMed ID: 19255824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
    Hayoz D; Zappe DH; Meyer MA; Baek I; Kandra A; Joly MP; Mazzolai L; Haesler E; Periard D
    J Clin Hypertens (Greenwich); 2012 Nov; 14(11):773-8. PubMed ID: 23126349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
    Raij L; Egan BM; Zappe DH; Purkayastha D; Samuel R; Sowers JR
    J Clin Hypertens (Greenwich); 2011 Oct; 13(10):731-8. PubMed ID: 21974760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
    Destro M; Cagnoni F; D'Ospina A; Ricci AR; Demichele E; Peros E; Zaninelli A; Preti P
    Vasc Health Risk Manag; 2010 Apr; 6():253-60. PubMed ID: 20407632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
    Everett BM; Glynn RJ; Danielson E; Ridker PM;
    Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial.
    White WB; Calhoun DA; Samuel R; Taylor AA; Zappe DH; Purkayastha D
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):450-8. PubMed ID: 18550935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.